Table 2.
Treatments and clinical outcomes in pregnant and non-pregnant reproductive-aged women with coronavirus disease 2019 (COVID-19)
| Treatments and outcomes | Pregnant women (n = 28) |
Non-pregnant women (n = 54) |
p-value |
|---|---|---|---|
| Treatments | |||
| Antivirals | |||
| Ribavirin | 20 (71.4) | 19 (35.2) | < 0.001 |
| Umifenovir | 1 (3.6) | 11 (20.4) | – |
| Ribavirin + umifenovir | 0 (0.0) | 17 (31.5) | – |
| Interferon alpha inhalation | 0 (0.0) | 7 (13.0) | – |
| Antibiotics | 24 (85.7%) | 47 (87%) | |
| Cephalosporin | 20 (71.4) | 9 (16.7) | < 0.001 |
| Quinolone | 4 (14.3) | 6 (11.1) | – |
| Cephalosporins + quinolone | 0 (0) | 32 (59.3) | – |
| Corticosteroids | 4 (14.3) | 21 (38.9) | 0.041 |
| Gamma globulin | 3 (10.7) | 19 (35.2) | 0.035 |
| Outcomes | |||
| Hospitalization | 7 (25) | 0 (0) | < 0.001 |
| Discharge | 21 (75) | 54 (100) | – |
| Death | 0 (0) | 0 (0) | – |
| Virus clearance time (days) | 12 (8–26.5) | 18 (12–25) | 0.613 |
| Length of hospital stay (days) | 14 (12–22.25) | 18 (10.25–22) | 0.635 |